Showing 4271-4280 of 6036 results for "".
- RetinAI Joins Ryan Initiative for Macular Research AMD Consortiumhttps://modernod.com/news/retinai-joins-ryan-initiative-for-macular-research-amd-consortium/2481987/RetinAI Medical announced that they are now joining the Ryan Initiative for Macular Research (RIMR) Age-related Macular Degeneration (AMD) Imaging Consortium, a non-profit group of physicians, researchers, and industry partners working together to define optimal biomarkers and endpoints in AMD.</
- Skye Bioscience Begins Phase 2 Study of SBI-100 Ophthalmic Emulsion to Treat Glaucomahttps://modernod.com/news/skye-bioscience-begins-phase-2-study-of-sbi-100-ophthalmic-emulsion-to-treat-glaucoma/2481984/Skye Bioscience, which is developing drugs targeting the endocannabinoid system and focusing on glaucoma and metabolic conditions, announced it has treated the first patient in its phase 2 clinical trial evaluating SBI-100 ophthalmic emulsion’s ability to lower IOP as well as safe
- NORA Names New Executive and Advisory Board Membershttps://modernod.com/news/nora-names-new-executive-and-advisory-board-members/2481983/The Neuro-Optometric Rehabilitation Association, International (NORA) announced the appointments of its new Executive and Advisory Board members. NORA is an interdisciplinary group of professionals dedicated to providing a complete ocular health evaluation and optimum visual rehabilitation educat
- Ocuphire Pharma Names Joseph Schachle as COOhttps://modernod.com/news/ocuphire-pharma-names-joseph-schachle-as-coo/2481981/Ocuphire Pharma announced the appointment of Joseph (Joe) K. Schachle, MBA, into the newly created role of Chief Operating Officer, effective immediately. Ocuphire is a clinical-stage company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refra
- Emily Chew, MD, Named NIH Distinguished Investigatorhttps://modernod.com/news/emily-chew-md-named-nih-distinguished-investigator/2481980/Emily, Chew, MD, has been promoted to the title of NIH Distinguished Investigator for her work as a care provider and clinical trialist. Dr. Chew directs National Eye Institute's Division of Epidemiology and Clinical Applications (DECA). An ophthalmologist, she specializes in c
- Oxurion to File for Bankruptcy After Failed DME Trialhttps://modernod.com/news/oxurion-to-file-for-bankruptcy-after-failed-dme-trial/2481978/Oxurion said it has decided to file for bankruptcy after announcing topline data from its KALAHARI phase 2, Part B trial for diabetic macular edema (DME). The trial did not demonstrate that its novel PKal inhibitor, THR-149, improved vision as much as the comparator,
- Inflammasome Therapeutics to Enter Clinic with Treatment for Dry AMDhttps://modernod.com/news/inflammasome-therapeutics-to-enter-clinic-with-treatment-for-dry-amd/2481974/Inflammasome Therapeutics, developer of a new class of inflammasome inhibitor drugs called Kamuvudines, announced the FDA has granted approval for the opening of a phase 1/2 clinical trial of the company’s drug for the treatment of geographic atrophy (GA). This is the first clinical tr
- Injectsense and Injectpower Secure $9.4M to Support Injectsense's First-in-Human Studies for Sensors that Continuously Measure IOPhttps://modernod.com/news/injectsense-and-injectpower-secure-94m-to-support-injectsenses-first-in-human-studies-for-sensors-that-continuously-measure-iop/2481973/Injectsense and sister company Injectpower, a developer of ultra-miniature solid-state microbatteries for medical applications, announced combined funding of $9.4 million to bring highly integrated autonomous implantable devices—smaller than a grai
- Regenxbio Presents New Data on Investigational AAV Therapeutic for Retinal Conditionshttps://modernod.com/news/regenxbio-presents-new-data-on-investigational-aav-therapeutic-at-aao/2481967/At the American Academy of Ophthalmology 2023 Annual Meeting in San Francisco, new data was presented for Regenxbio's ABBV-RGX-314, an investigational one-time AAV therapeutic being developed in collaboration with AbbVie for the treatment of wet age-related macular degener
- Orcam Technologies Unveils Orcam Read 3 AI-Driven Solution for People with Low Vision and Visual Impairmentshttps://modernod.com/news/orcam-technologies-unveils-orcam-read-3-ai-driven-solution-for-people-with-low-vision-and-visual-impairments/2481965/OrCam Technologies has introduced the OrCam Read 3, which is designed to improve the way people with vision loss and reading difficulties interact with visual materials. User point the device at a book, computer screen, product packaging or any text, and the AI technology will loudly and cle